The world asthma and COPD therapies market will reach $33.1bn in 2014, Says the New Study on ASDReports

Wednesday 17 December 2014, Amsterdam

A new report now available on ASDReports, predicts that the world market for asthma and COPD therapies will reach $33.1bn in 2014. This forecast and others appear in Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for Leading Companies, published in October 2014. Visiongain is a business information provider based in London, UK.

Asthma and COPD therapies include inhaled beta-agonists, anticholinergic agents, anti-inflammatory drugs and combination drugs used to control the symptoms of asthma and COPD and prevent exacerbations. The market for these drugs is maturing with generic competition expected for several leading products in 2014-2024. However, growth opportunities remain in areas such as monoclonal bodies and once-daily combination therapies. The R&D pipeline for anti-inflammatory drugs is particularly strong. GSK, Boehringer Ingelheim and AstraZeneca dominate the market in 2014 but will be increasingly challenged by generic drug companies.

Thomas Ling, a senior pharmaceutical and medical devices industry analyst and consultant in visiongain, said: “The asthma and COPD therapies market is becoming more complex. Generic versions of Advair have now reached the market, while market leaders continue to innovate with more advanced inhaler devices and novel combination therapies. There is greater recognition of different patient phenotypes in asthma and COPD. This is especially the case in severe asthma, as new monoclonal antibodies target specific inflammatory mediators in subgroups of patients. Telehealth systems may also allow better monitoring of patient adherence and treatment outcomes. All this suggests a shift towards personalised medicine in asthma and COPD, which will require manufacturers to plan accordingly for the future.”

Visiongain’s brand new 335 page report provides revenue forecasts to 2024 for the world asthma and COPD therapies market and leading submarkets. It forecasts sales for 27 leading Asthma and COPD drugs to 2024, including promising products currently in development. The report provides sales forecasts for the bronchodilator monotherapy, anti-inflammatory drugs and combination drugs segments of the market. The report also profiles seven leading companies in the asthma and COPD therapies market, including asthma and COPD revenue forecasts to 2024, – AstraZeneca, Boehringer Ingelheim, GSK, Merck & Co., Novartis, Roche and Teva. It also discusses key marketed products, products in the development pipeline, commercial news, and analysis of strengths, weaknesses, opportunities and threats. It includes six exclusive interviews with industry experts regarding current market trends. The report also includes a Porter’s Five Forces analysis to understand the degree of competitiveness in this market.